• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Owens & Minor Inc.

    6/6/25 4:30:28 PM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email
    8-K
    false 0000075252 0000075252 2025-06-05 2025-06-05
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report: June 5, 2025

     

     

    OWENS & MINOR, INC.

    (Exact name of Registrant as specified in charter)

     

     

     

    Virginia   001-09810   54-1701843

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    file number)

     

    (I.R.S. employer

    identification no.)

     

    10900 Nuckols Road, Suite 400  
    Glen Allen, Virginia   23060
    (Address of principal executive offices)   (Zip code)

     

    Post Office Box 27626,  
    Richmond, Virginia   23261-7626
    (Mailing address of principal executive offices)   (Zip code)

    Registrant’s telephone number, including area code (804) 723-7000

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $2 par value per share   OMI   New York Stock Exchange

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.04.

    Triggering Events That Accelerate or Increase a Direct Financial Obligation under an Off-Balance Sheet Arrangement.

    As previously disclosed, on June 3, 2025, Owens & Minor, Inc. (the “Company”), Rotech Healthcare Holdings Inc., a Delaware corporation (“Rotech”), and Hitchcock Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), mutually agreed to terminate the Agreement and Plan of Merger, dated as of July 22, 2024, by and among the Company, Rotech, Merger Sub and Shareholder Representative Services LLC, pursuant to which the Company agreed to acquire Rotech on the terms and subject to the conditions therein. The termination was effective as of June 5, 2025.

    In connection with such termination, pursuant to the terms of the indenture dated as of April 4, 2025, by and among the Company, the guarantors named therein and Regions Bank, as trustee and as collateral agent (the “Indenture”), under which the Company issued $1,000,000,000 aggregate principal amount of 10.000% Senior Secured Notes due 2030 (the “Notes”), the Company is required to redeem such Notes.

    On June 5, 2025, the Company issued a notice of special mandatory redemption to holders of the Notes.

    Pursuant to the terms of the Indenture, the Company will redeem the Notes on June 10, 2025 (the “Redemption Date”) at a redemption price equal to 100% of the aggregate principal amount of the Notes, plus accrued and unpaid interest, to, but excluding, the Redemption Date. This Current Report on Form 8-K does not constitute a notice of redemption with respect to the Notes.

    Forward-Looking Statements

    This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s financial position and the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. The Company cautions readers of this communication that such “forward looking statements,” wherever they occur in this Current Report or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward-looking statements.”

    Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our ability to successfully complete a transaction related to the potential sale of our Products & Healthcare Services segment; uncertainties related to trade policy and tariffs; increasing competitive and pricing pressures in the marketplace; our ability to retain existing and attract new customers and our dependence on sales to certain customers; our dependence on certain vendors, suppliers and third-parties for key components, raw materials, finished goods, equipment and services; our ability to successfully identify, close, manage or integrate acquisitions; our ability to successfully implement our strategic initiatives; our ability to successfully manage our international operations, including risks associated with changes in international trade regulations, foreign currency volatility, adverse tax consequences, and other risks of operating in international markets; uncertainties related to, and our ability to adapt to and comply with, changes in government regulations, including healthcare, tax and product licensing laws and regulations; risks arising from possible violations of legal, regulatory or licensing requirements of the markets in which we operate; uncertainties related to general economic, regulatory and business conditions, including tariffs, and our ability to adapt to changes in product pricing and other terms of purchase by suppliers of product; our ability to meet the terms to qualify for supplier funding programs; the ability of customers and suppliers to meet financial commitments due to us; changes in manufacturer preferences between direct sales and wholesale distribution; changing trends in customer profiles and ordering patterns; our ability to manage operating expenses and improve operational efficiencies; availability of, and our ability to access, special inventory buying opportunities; our ability to continue to obtain financing at reasonable rates and to manage financing costs and interest rate risk, and our ability to refinance, extend or repay our substantial indebtedness; our ability to attract and retain talented and qualified teammates; recalls of any of our products, or safety risks or the


    discovery of serious safety issues with our products; changes, delays and uncertainties in the reimbursement process; our ability to adequately establish, maintain, protect and enforce our intellectual property and proprietary rights as well as avoid infringement, misappropriation or other violations of the intellectual property and proprietary rights of third parties; our ability to engage in transactions that may be limited by the restrictive covenants in our credit facilities and existing notes; the risk that information systems are interrupted or damaged or fail for any extended period of time, that new information systems are not successfully implemented or integrated, or that there is a data security breach in our information systems or a third party’s information systems that impacts our business; risks related to public health crises or future outbreaks of health crises or other adverse public health developments such as the novel coronavirus (COVID-19) global pandemic; the risk of an impairment to goodwill or other long-lived assets; our ability to timely or adequately respond to technological advances; our failure to adequately insure against losses, including from substantial claims and litigation; our ability to meet performance targets specified by customer contracts under contractual commitments; our capitation arrangements may prove unprofitable if actual utilization rates exceed our assumptions; the outcome of outstanding and any future litigation, including product and professional liability claims; and volatility in the price of our common stock and securities.

    Additional factors that could cause the Company’s actual outcomes or results to differ materially from those described in these forward-looking statements can be found in the “Risk Factors” sections of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in this Current Report and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          OWENS & MINOR, INC.
    Date: June 6, 2025     By:  

    /s/ Heath H. Galloway

        Name:   Heath H. Galloway
        Title:   Executive Vice President, General Counsel & Corporate Secretary
    Get the next $OMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    4/1/2022$43.00Neutral
    Credit Suisse
    More analyst ratings

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition

      OMI Remains Committed to Continued Growth in the Strong Home-based Care Market Will Focus on Deleveraging & Driving Profitable Growth Owens & Minor, Inc. (NYSE:OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare. Owens & Minor will also redeem the $1 billion of notes issued in April 2025, which include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders which would have bee

      6/5/25 9:00:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/10/25 9:43:55 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/7/25 8:21:15 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $27,386,158 worth of shares (2,893,412 units at $9.47) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      3/4/25 9:07:16 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    SEC Filings

    See more
    • SEC Form 8-K filed by Owens & Minor Inc.

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      6/6/25 4:30:28 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      6/5/25 9:12:33 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SD filed by Owens & Minor Inc.

      SD - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/28/25 4:10:06 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Financials

    Live finance-specific insights

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports Fourth Quarter & Full Year Financial Results and Announces Sale Process Underway for Products & Healthcare Services Segment

      Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod

      2/28/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Owens & Minor upgraded by Citigroup with a new price target

      Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

      7/19/24 7:41:01 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Owens & Minor with a new price target

      Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

      2/26/24 8:10:20 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Owens & Minor with a new price target

      Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00

      1/3/24 8:05:34 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      11/12/24 10:32:12 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/13/24 5:12:07 PM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/12/24 5:29:41 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    See more
    • Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

      Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

      6/22/22 6:50:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CHRO Stone Jennifer A covered exercise/tax liability with 5,764 shares, decreasing direct ownership by 5% to 110,327 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      6/4/25 4:39:16 PM ET
      $OMI
      Medical Specialities
      Health Care
    • EVP,General Counsel & CorpSecy Galloway Heath H covered exercise/tax liability with 1,768 shares, decreasing direct ownership by 1% to 117,044 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/20/25 7:55:01 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Rollins Carissa was granted 28,914 shares, increasing direct ownership by 116% to 53,902 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:11:21 PM ET
      $OMI
      Medical Specialities
      Health Care